argenx company profile
Secondary listing. The primary listing is argenx · NASDAQ (USD)
Company profile
argenx has 1,863 employees and is headquartered in Amsterdam, Netherlands.
Based in Amsterdam, the Netherlands, argenx SE was incorporated in 2008 and operates as a commercial-stage biopharmaceutical company focused on autoimmune diseases. Its marketed medicines include VYVGART for generalized myasthenia gravis (gMG) and immune thrombocytopenia (ITP), and VYVGART HYTRULO for gMG and chronic inflammatory demyelinating polyneuropathy (CIDP). The pipeline centres on efgartigimod, which is being studied in several other conditions, alongside candidates targeting FcRn, IL-6 and immunoglobulin A. The company sells in the United States, Japan, China and other markets, and has partnerships with Zai Lab, Halozyme Therapeutics, OncoVerity and AbbVie.
In the fiscal year ended December 2025, argenx reported revenue of USD 4.2 billion, up 88.4% from the previous year, and net income of USD 1.3 billion. The United States accounted for 83.2% of revenue, with Japan at 4.9% and China at 1.6%. The company employed 1,863 people. Its shares also trade on NASDAQ.
Company facts
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Belgium
- Headquarters
- Laarderhoogtweg 25, 1101 EB, Amsterdam
- Employees
- 1,863
- Chief executive
- Karen Massey
- Founded
- 2008
- Fiscal year
- January - December
- Listing
- ARGX · Euronext Brussels
- Indices
- EURO STOXX 50
- Currency
- EUR
- ISIN
- NL0010832176
- Website
- argenx.com
argenx and its competitors
The most similar companies by business and size
| Company | Country | Market cap | Employees | Operating margin | P/E (trailing 12 months) |
|---|---|---|---|---|---|
| argenxARGX | Belgium | $61.05B | 1,863 | 31.9% | 35.3 |
| BeOne MedicinesONC | United States | $47.58B | 12,000 | 17.8% | 53.4 |
| ModernaMRNA | United States | $90.38B | 4,700 | -80.8% | — |
| Royalty PharmaRPRX | United States | $39.85B | 100 | 64.4% | 45.3 |
| Revolution MedicinesRVMD | United States | $37.27B | 883 | -853.0% | — |
| Regeneron PharmaceuticalsREGN | United States | $98.84B | 15,410 | 30.4% | 21.1 |
Competitors: same or related industry, same region first, then the closest market capitalization. Market cap converted into US dollars at the latest exchange rates; P/E over the last 12 months, not shown when negative.
